A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Haematopoietic Stem Cell Mobilisation (BED)

Trial Profile

A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Haematopoietic Stem Cell Mobilisation (BED)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2017

At a glance

  • Drugs Bendamustine (Primary) ; Dexamethasone; Etoposide; Filgrastim
  • Indications B cell lymphoma; Hodgkin's disease; Multiple myeloma; Stem cell mobilisation; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2016 Results (n = 34) published in the Bone Marrow Transplantation.
    • 08 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top